Matisse Pharmaceuticals

Matisse Pharmaceuticals is a Dutch biotech advancing a novel therapeutic approach to treat life-threatening inflammation, particularly sepsis, by targeting extracellular cytotoxic histones. The company has progressed its lead asset, isupartob sodium, into clinical trials, having recently completed a healthy volunteer study. With a clear mission to save millions of lives, Matisse operates as a private, pre-revenue entity, leveraging strategic partnerships to advance its pipeline in a high-need, underserved market.

Platform focused on developing agents that bind to and neutralize extracellular cytotoxic histones, a key driver of inflammation and organ damage in conditions like sepsis.

The competitive landscape for direct histone antagonists in sepsis is nascent, positioning Matisse as a potential first mover. However, it competes indirectly with the entire standard of care and numerous failed attempts at immunomodulation in sepsis. Broader competition includes large pharma and biotech companies investigating other anti-inflammatory targets (e.g., IL-6, complement) for septic shock.